Low-dose ruxolitinib as first-line therapy for acute graft-versus-host disease (aGVHD) increases the risk of Epstein-Barr virus (EBV) reactivation but not posttransplant lymphoproliferative disease (PTLD)
Qian, Kun; Xing, Shuangyi; Wei, Yujun; Wang, Lili; Yang, Jingjing; Li, Fei; Gu, Zhenyang; Wang, Nan; Dou, Liping; Liu, Daihong.png)
Share.png)
Save The global landscape of particle beam radiotherapy trials over the past 15 yearsChen, Wei; Wu, Chenfei; Xiao, Mingying; Chen, Runzhe; Guo, Lanlan; Hu, Haoyue; Li, Xuan; Dong, Baiqiang; Huang, Yuanyang; Chen, Ming Share Save Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancerJalali, Amirhossein; Moghaddam, Shirin; McGuire, Andrew; Joyce, Doireann P.; Carr, Bridget; O'leary, Diarmuid; Bourke, Emer; O'Neill, Ciaran; Kerin, Michael J.; Gillespie, Paddy; Brown, James A. L. Share Save Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistanceShaikat, Abdul Halim; Azad, S. M. Asadul Karim; Tamim, Md Azizur Rahman; Ullah, Mohammed Sailim; Amin, Mohammad Nurul; Sabbir, Mofazzal K.; Tarun, Md Towhidul Islam; Mostaq, Md Saqline; Sabrin, Shohana; Mahmud, Md Zihad; Mahmud, Md Ashiq Share Save Reduced cytomegalovirus reactivation and viremia without increasing GVHD after URD-PBSCT: A prospective study using targeted ATG dosing strategyChen, Sheng; Wang, Lu; Luan, Songhua; Wang, Haitao; Du, Jishan; Ge, Dongxue; Li, Fei; Wu, Yongli; Gu, Zhenyang; Dou, Liping; Liu, Daihong Share Save 
.png){kind=icon}
.png){kind=icon}
Not logged in.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
